View Future GrowthRenovaCare 過去の業績過去 基準チェック /06RenovaCareの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Sep 2022最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Nov 15RenovaCare, Inc. announced delayed 10-Q filingOn 11/14/2022, RenovaCare, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 12Pomerantz LLP Announces A Class Action Lawsuit Has Been Filed Against RenovaCare, IncPomerantz LLP announces that a class action lawsuit has been filed against RenovaCare, Inc. and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-13930, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired RenovaCare securities between August 14, 2017 and May 28, 2021, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").お知らせ • Jul 23RenovaCare, Inc Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound HealingRenovaCare, Inc. provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient. Currently, CELLMIST 1, the clinical trial is activated and screening patients at its first burn center. The Company plans to expand its clinical trial to up to four centers in the United States. One site is currently under active negotiation; another candidate site has voluntarily withdrawn from consideration; a fourth clinical site has decided to defer continued negotiations to a later date. The CELLMIST 1 clinical study plans to enroll 14 human subjects between 18 and 65 years old that have partial-thickness, second-degree thermal burn wounds encompassing < 30% total body surface area. Each enrolled subject will be treated within seven days of the burn incident with their own skin cells isolated by the manual CellMist™ System and applied topically onto the burn wound(s) with the Electronic SkinGun™ spray device. Seven follow-up visits over 12 months will evaluate the safety and recovery of each subject.お知らせ • Jun 08RenovaCare, Inc. Clinical Trial to Start At U.S. Burn CentersRenovaCare, Inc. announced that it is initiating a clinical trial at four burn centers in the United States. This follows the Company’s recent Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). The clinical trial, designated CELLMIST-1, utilizes electronic SkinGun™ spray device and CellMist™ System to render the skin and stem cells uniquely from both the epidermal and dermal layers of the patient’s own skin tissue and then topically spray these cells onto burn wounds to facilitate wound healing. This clinical study will evaluate the safety and feasibility of the Company’s autologous skin stem cell therapy for the treatment of deep second-degree, partial-thickness burn wounds in adults. The CELLMIST-1 clinical study is slated to start enrollment this week at the Burn Center of MedStar Washington Hospital Center (Washington D.C.). In coming weeks, clinical study sites at UMC Burn Center at University Medical Center New Orleans (New Orleans, LA), University of Florida Health Shands Burn Center (Gainesville, FL), and the Regional Burn Center, Tampa General Hospital, University of South Florida Medical Center (Tampa, FL) will open for enrollment.お知らせ • May 07FDA Grants RenovaCare, Inc. Full Investigational Device Exemption Approval for Safety and Feasibility Clinical TrialRenovaCare, Inc. announced that its investigational device exemption (IDE) application has been granted full approval by the U.S. Food and Drug Administration (FDA). This approval enables the company to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds using skin cells obtained directly from the burn patient. The clinical trial protocol is an open-label, single-arm clinical study that will enroll 14 adult burn subjects with partial-thickness second degree thermal burn wounds. The company expects to conduct the clinical study at four U.S. burn centers over twelve months. Spraying Cells onto Burns and Wounds: to date, over 70 patients with various types of burns have been treated in investigator initiated clinical case studies utilizing the technology underlying the company’s SkinGun™ and CellMist™ System, which the company has developed as a potential alternative to skin grafting and other treatment options, such as in vitro cultured skin epithelial cells that require a specialized and expensive external laboratory. Clinical outcomes of these early experimental studies have been peer-reviewed and published in several medical journals, including Burns and Annals of Plastic Surgery. In late 2019, the company was issued a patent allowing the company’s novel SkinGun™ spray device to spray a variety of tissues and cells, thus opening the door for its potential application in the regeneration of other tissues, beyond skin.お知らせ • Oct 06Renovacare, Inc. Announces Board ChangesRenovaCare, Inc. announced that Alan L. Rubino, Chief Executive Officer and President, has been elected to the additional role of Chairman of the Board of RenovaCare effective October 1, 2020. Mr. Rubino replaces Harmel S. Rayat as Chairman of the Board, who resigned from the Board and as Chairman on the same date. Mr. Rubino was named President and CEO, and a member of the company’s Board of Directors, in November 2019 to build a highly experienced leadership team with a proven track record to focus the company on its planned transition from a pre-clinical stage to a development/commercial stage entity.収支内訳RenovaCare の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:RCAR 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 220-62230 Jun 220-75231 Mar 220-63331 Dec 210-42330 Sep 210-62430 Jun 210-73431 Mar 210-94531 Dec 200-106430 Sep 200-85330 Jun 200-65231 Mar 200-44131 Dec 190-33130 Sep 190-32130 Jun 190-22131 Mar 190-22031 Dec 180-22030 Sep 180-32030 Jun 180-32131 Mar 180-42131 Dec 170-42130 Sep 170-32030 Jun 170-32031 Mar 170-21031 Dec 160-22030 Sep 160-22030 Jun 160-22031 Mar 160-22031 Dec 150-11030 Sep 150-110質の高い収益: RCARが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: RCARの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: RCARの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: RCARの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: RCARの過去 1 年間の収益成長がBiotechs業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: RCARは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 01:55終値2026/05/26 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋RenovaCare, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 15RenovaCare, Inc. announced delayed 10-Q filingOn 11/14/2022, RenovaCare, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 12Pomerantz LLP Announces A Class Action Lawsuit Has Been Filed Against RenovaCare, IncPomerantz LLP announces that a class action lawsuit has been filed against RenovaCare, Inc. and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-13930, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired RenovaCare securities between August 14, 2017 and May 28, 2021, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").
お知らせ • Jul 23RenovaCare, Inc Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound HealingRenovaCare, Inc. provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient. Currently, CELLMIST 1, the clinical trial is activated and screening patients at its first burn center. The Company plans to expand its clinical trial to up to four centers in the United States. One site is currently under active negotiation; another candidate site has voluntarily withdrawn from consideration; a fourth clinical site has decided to defer continued negotiations to a later date. The CELLMIST 1 clinical study plans to enroll 14 human subjects between 18 and 65 years old that have partial-thickness, second-degree thermal burn wounds encompassing < 30% total body surface area. Each enrolled subject will be treated within seven days of the burn incident with their own skin cells isolated by the manual CellMist™ System and applied topically onto the burn wound(s) with the Electronic SkinGun™ spray device. Seven follow-up visits over 12 months will evaluate the safety and recovery of each subject.
お知らせ • Jun 08RenovaCare, Inc. Clinical Trial to Start At U.S. Burn CentersRenovaCare, Inc. announced that it is initiating a clinical trial at four burn centers in the United States. This follows the Company’s recent Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). The clinical trial, designated CELLMIST-1, utilizes electronic SkinGun™ spray device and CellMist™ System to render the skin and stem cells uniquely from both the epidermal and dermal layers of the patient’s own skin tissue and then topically spray these cells onto burn wounds to facilitate wound healing. This clinical study will evaluate the safety and feasibility of the Company’s autologous skin stem cell therapy for the treatment of deep second-degree, partial-thickness burn wounds in adults. The CELLMIST-1 clinical study is slated to start enrollment this week at the Burn Center of MedStar Washington Hospital Center (Washington D.C.). In coming weeks, clinical study sites at UMC Burn Center at University Medical Center New Orleans (New Orleans, LA), University of Florida Health Shands Burn Center (Gainesville, FL), and the Regional Burn Center, Tampa General Hospital, University of South Florida Medical Center (Tampa, FL) will open for enrollment.
お知らせ • May 07FDA Grants RenovaCare, Inc. Full Investigational Device Exemption Approval for Safety and Feasibility Clinical TrialRenovaCare, Inc. announced that its investigational device exemption (IDE) application has been granted full approval by the U.S. Food and Drug Administration (FDA). This approval enables the company to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds using skin cells obtained directly from the burn patient. The clinical trial protocol is an open-label, single-arm clinical study that will enroll 14 adult burn subjects with partial-thickness second degree thermal burn wounds. The company expects to conduct the clinical study at four U.S. burn centers over twelve months. Spraying Cells onto Burns and Wounds: to date, over 70 patients with various types of burns have been treated in investigator initiated clinical case studies utilizing the technology underlying the company’s SkinGun™ and CellMist™ System, which the company has developed as a potential alternative to skin grafting and other treatment options, such as in vitro cultured skin epithelial cells that require a specialized and expensive external laboratory. Clinical outcomes of these early experimental studies have been peer-reviewed and published in several medical journals, including Burns and Annals of Plastic Surgery. In late 2019, the company was issued a patent allowing the company’s novel SkinGun™ spray device to spray a variety of tissues and cells, thus opening the door for its potential application in the regeneration of other tissues, beyond skin.
お知らせ • Oct 06Renovacare, Inc. Announces Board ChangesRenovaCare, Inc. announced that Alan L. Rubino, Chief Executive Officer and President, has been elected to the additional role of Chairman of the Board of RenovaCare effective October 1, 2020. Mr. Rubino replaces Harmel S. Rayat as Chairman of the Board, who resigned from the Board and as Chairman on the same date. Mr. Rubino was named President and CEO, and a member of the company’s Board of Directors, in November 2019 to build a highly experienced leadership team with a proven track record to focus the company on its planned transition from a pre-clinical stage to a development/commercial stage entity.